Skip to main content
Equibles

Eversept Partners, LP

Position in REPL — Replimune Group, Inc.

CIK 1697013 NEW YORK, NY
Back to REPL Full portfolio

Position in REPL

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$6,534,089
+$3,972,403 QoQ
Shares Held
590,252
+76.3% QoQ
Ownership
0.626%
of shares outstanding
% of Portfolio
0.36%
of 13F equity value
Holder Rank
#34
of 199 holders
Holding Since
Sep 2025
3 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in REPL Over Time

Shares Held

Position Value (USD)

Derivatives in REPL

reported options exposure · as of Mar 31, 2026
CallValue
$397,800
CallShares
52,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Eversept Partners, LP holds $859,319,346 across 72 Biotechnology names. REPL ranks #31 (0.8% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ABVX
Abivax S.A.
 913,880 $121,783,648
2 VERA
Vera Therapeutics, Inc.
 2,212,770 $94,949,960
3 CLDX
Celldex Therapeutics, Inc.
 1,785,941 $66,454,864
4 SNDX
Syndax Pharmaceuticals Inc
 2,798,210 $61,168,870
5 IONS
Ionis Pharmaceuticals Inc
 664,684 $52,702,794
6 TVTX
Travere Therapeutics, Inc.
 798,973 $45,389,656
7 PCVX
Vaxcyte, Inc.
 629,952 $36,619,109
8 GERN
Geron Corp
 18,717,422 $23,958,300

All Filings in REPL

Export CSV
4 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $6,534,089 590,252
2026-03-31 $2,561,686 334,861
2026-03-31 $397,800 52,000
2025-09-30 $251,366 59,992